Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Eli Lilly to Make Bebtelovimab Commercially Available

Eli Lilly to Make Bebtelovimab Commercially Available

Eli Lilly said it will make its COVID-19 drug bebtelovimab commercially available to U.S. states and territories, hospitals and other providers later this month.

The FDA authorized the monoclonal antibody for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients aged 12 years and older and weighing at least 88 pounds who are at high risk of developing severe COVID-19 and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.

Laboratory testing has shown that bebtelovimab, which works by binding to the spike protein of the SARS-CoV-2 virus that causes COVID-19 infection, is effective against the Omicron variant.

Lilly said the drug will be available in the week of Aug.15, before the anticipated depletion of the U.S. government’s currently available supply.

August 5, 2022


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies